BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 35489038)

  • 21. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
    Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
    Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
    Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
    Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
    Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
    Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer.
    Park S; Hong TH; Hwang S; Heeke S; Gay CM; Kim J; Jung HA; Sun JM; Ahn JS; Ahn MJ; Cho JH; Choi YS; Kim J; Shim YM; Kim HK; Byers LA; Heymach JV; Choi YL; Lee SH; Park K
    EBioMedicine; 2024 Apr; 102():105062. PubMed ID: 38492534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.
    Tenjin Y; Matsuura K; Kudoh S; Usuki S; Yamada T; Matsuo A; Sato Y; Saito H; Fujino K; Wakimoto J; Ichimura T; Kohrogi H; Sakagami T; Niwa H; Ito T
    Lab Invest; 2020 Dec; 100(12):1575-1588. PubMed ID: 32801334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
    Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
    Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
    Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
    Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR; Curran WJ; Ivanov AA; Fu H; Lonial S; Ramalingam SS; Sun SY; Waller EK; Sica GL
    J Thorac Oncol; 2021 Mar; 16(3):464-476. PubMed ID: 33248321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
    Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
    Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
    Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
    Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
    Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
    Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer.
    Lang C; Lantos A; Megyesfalvi Z; Egger F; Hoda MA; Mosleh B; Klikovits T; Oberndorfer F; Timelthaler G; Ferencz B; Fillinger J; Schwendenwein A; Querner AS; Boettiger K; Renyi-Vamos F; Hoetzenecker K; Laszlo V; Schelch K; Dome B
    ESMO Open; 2022 Dec; 7(6):100631. PubMed ID: 36399951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
    Kawai H; Matsuoka R; Ito T; Matsubara D
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors.
    Sato Y; Okamoto I; Kameyama H; Kudoh S; Saito H; Sanada M; Kudo N; Wakimoto J; Fujino K; Ikematsu Y; Tanaka K; Nishikawa A; Sakaguchi R; Ito T
    Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33202998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Ikematsu Y; Tanaka K; Toyokawa G; Ijichi K; Ando N; Yoneshima Y; Iwama E; Inoue H; Tagawa T; Nakanishi Y; Okamoto I
    Lung Cancer; 2020 Aug; 146():97-104. PubMed ID: 32526603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.
    Costanzo F; Martínez Diez M; Santamaría Nuñez G; Díaz-Hernandéz JI; Genes Robles CM; Díez Pérez J; Compe E; Ricci R; Li TK; Coin F; Martínez Leal JF; Garrido-Martin EM; Egly JM
    EMBO Mol Med; 2022 Apr; 14(4):e14841. PubMed ID: 35263037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small cell lung cancer - news in the tumour´s biology.
    Pavlíčková K; Matěj R
    Cesk Patol; 2023; 59(1):18-22. PubMed ID: 37072275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.
    Pearsall SM; Humphrey S; Revill M; Morgan D; Frese KK; Galvin M; Kerr A; Carter M; Priest L; Blackhall F; Simpson KL; Dive C
    J Thorac Oncol; 2020 Dec; 15(12):1836-1843. PubMed ID: 32721553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
    Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
    Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.